Лучевая терапия при олигометастатическом раке
Аннотация
Современные подходы к лечению больных с метастатическими злокачественными опухолями значительно изменились за последнее десятилетие. Вместо сугубо паллиативной системной или только поддерживающей терапии немалой части больных проводится и активное локальное воздействие не только на первичную опухоль, но и на метастатические очаги, и ряд исследований демонстрирует преимущество такого подхода. В этом обзоре представлена информация о роли лучевой терапии как локального метода в лечении онкологических больных с олигометастазами.
Об авторах
Н. В. Деньгина
ГУЗ «Областной клинический онкологический диспансер»
Россия
Россия
Наталья В. Деньгина, к. м. н., заведующая радиологическим отделением, ГУЗ «Областной клинический онкологический диспансер», директор по лечебным вопросам Центра Томотерапии «R-Spei»
Ульяновск
Т. В. Митин
Университет Здоровья и Науки Орегона
Соединённые Штаты Америки
Соединённые Штаты Америки
Тимур В. Митин, д. м. н., отделение радиационной медицины
Портленд
И. В. Тимофеев
Институт онкологии «Хадасса Москва»
Россия
Россия
Илья В. Тимофеев, онколог, директор
Москва
С. В. Усычкин
Институт онкологии «Хадасса Москва»; Медицинский центр «Медскан»
Россия
Россия
Сергей В. Усычкин, к. м. н., заведующий отделением лучевой терапии, Институт онкологии «Хадасса Москва», заведующий отделением лучевой терапии, Медицинский центр «Медскан»
Москва
Список литературы
1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13 (1):8–10.
2. Lievens I, Guckenberger M, Gomez D, et al. ESTRO-ASTRO OMD Consensus Document. Radiotherapy and Oncology 2020;148:157–166
3. Guckenberger M, Lievens Y, Bouma AB, et al. Characterization and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organization for Research and Treatment of Cancer consensus recommendation. The Lancet Oncology. 2020;21 (1):e18–28
4. Greco C, Pares O, Pimentel N, et al. Phenotype-Oriented Ablation of Oligometastatic Cancer with Single Dose Radiation Therapy. IJROBP 2019;104 (3):593–603
5. Arnold KM, Flynn NJ, Raben A, et al. The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules. Cancer Growth and Metastasis 2018;11:1–17
6. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013;14 (1):e28–37
7. Gomez DR, Blumenschein GR Jr, Lee JJ, et al: Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016;17:1672–1682
8. Gomez DR, Tang C, Zhang J, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non — Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol 2019;37:1558–1565
9. Iyengar P, Wardak Z, Gerber DE, et al: Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial. JAMA Oncol 2018;4: e173501
10. Palma DA, Olson R, Harrow S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol 2020;38
11. Petrelli F, Ghidini A, Cabiddu M, et al., Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis. Lung Cancer 2018;126:194–200
12. Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect Curr Probl Cancer 2016;40:25–37
13. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58:862–70.
14. Friedman D, Baird JR, Young KH et al. Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma. Hepatology Research 2016;47 (7): 702–714
15. Postow MA, Callahan MK, Barker CA, et al. Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. N Engl J Med 2012;366:925–931
16. Chicas-Sett R, Morales-Orue I, Castilla-Martinez J, et al. Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. Clinical and Translational Radiation Oncology 2018;9: P5–11
17. Chandra RA, Wilhite TJ, Balboni TA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab Oncoimmunology 2015; 4 (11):e1046028
18. Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumor immunogenicity. Nat Commun 2017;8:15618 DOI: 10.1038
19. Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects. Nature Reviews 2019;16:123–135.
20. US Department of Health & Human Services. CTCAE) v4.03. NIH. gov https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE
21. Tubin S, Popper HH, Brcic L. Novel stereotactic body radiation therapy (SBRT) — based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects. Radiation Oncology 2019;14:21
22. Zhang X., Niedermann G. OC - 0052: Abscopal effects with RT schedules extending to the effector phase of the antitumor T cell response. ESTRO 37 abstract book.
23. Marciscano AE, Ghasemzadeh A, Nirschl TR, et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer Research 2018;;24 (20):5058–5071.
24. Ho AY, Barker CA, Arnold BB, et al. A Phase 2 Clinical Trial Assessing the Efficacy and Safety of Pembrolizumab and Radiotherapy in Patients with Metastatic Triple-Negative Breast Cancer. Cancer 2020;126:850–860
25. Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE - 012 Study. J Clin Oncol 2016, 34 (21):2460–2467
26. Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE - 086 study. Ann Oncol 2019, 30 (3):397–404
27. Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1‑positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE - 086 study. Ann Oncol 2019, 30 (3):405–411
28. Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD - 1 blockade: the TONIC trial. Nat Med 2019;25 (6):920–928
29. Barroso-Sousa R, Krop IE, Trippa L, et al. A Phase II Study of Pembrolizumab in Combination with Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clinical Breast Cancer 2020, 20 (3):238–245
30. McBride S, Sherman E, Tsai CJ, et al. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol 2021;39 (1):30–37
31. Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncology 2019;5 (9):1276–1282
32. Welsh J, Menon H, Chen D, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I / II trial. Journal for ImmunoTherapy of Cancer 2020;8: e001001
33. Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2020;20: S2213–2600
34. Herbst RS, Garon EB, Kim DW, et al. Long-Term Outcomes and Retreatment Among Patients with Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE - 010 Study. J Clin Oncol 2020;38(14):1580-1590.
Для цитирования:
Деньгина Н.В., Митин Т.В., Тимофеев И.В., Усычкин С.В. Лучевая терапия при олигометастатическом раке. Злокачественные опухоли. 2020;10(3):5-14. https://doi.org/10.18027/2224-5057-2020-10-3-5-14
For citation:
Dengina N.V., Mitin T.V., Tsimafeyeu I.V., Usychkin S.V. Radiation therapy for oligometastatic cancer. Malignant tumours. 2020;10(3):5-14. (In Russ.) https://doi.org/10.18027/2224-5057-2020-10-3-5-14
Просмотров: 51
Послать статью по эл. почте 